Triciferol |
| Catalog No.GC61947 |
트리시페롤은 결합된 VDR 작용제 및 HDAC 길항제 활성과 함께 다중 리간드로 기능합니다. 트리시페롤은 VDR(IC50=87nM)에 직접 결합하고 여러 1,25D 표적 유전자에 대해 1,25D 유사 효능을 갖는 작용제로 기능합니다. 트리시페롤은 현저한 튜불린 과아세틸화를 유도하고 히스톤 아세틸화를 증가시킵니다. 항증식 및 세포독성 활동.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 957214-00-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Triciferol functions as a multiple ligand with combined VDR agonist and HDAC antagonist activities. Triciferol binds directly to the VDR (IC50=87 nM), and functions as an agonist with 1,25D-like potency on several 1,25D target genes. Triciferol induces marked tubulin hyperacetylation, and augments histone acetylation. Antiproliferative and cytotoxic activities[1].
Triciferol (0-10000 nM; 0-72 hours) is significantly more efficacious in suppressing the proliferation of estrogen receptor-negative human MDA-MB231 breast cancer cells[1].Treatment of MCF-7 cells with Triciferol (100-1000 nM) induces ≈2.5-fold higher rates of cell death than equimolar amounts of 1,25D[1].
References:
[1]. Tavera-Mendoza LE, et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc Natl Acad Sci U S A. 2008;105(24):8250-8255.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *